Daiichi Sankyo
Global pharmaceutical company with a rich legacy of innovation to help patients. See our community guidelines: http://t.co/qlLpvGG2xS.
Launch date
Employees
Market cap
€68.3b
Enterprise valuation
€60.5b (Public information from Sep 2024)
Share price
JPY4993 4568.T
Tokyo Japan (HQ)
Financials
Estimates*
JPY | 2021 | 2022 | 2023 | 2024 | 2025 | 2026 | 2027 |
---|---|---|---|---|---|---|---|
Revenues | 962.5b | 1.0t | 1.3t | 1.6t | 1.8t | 2.1t | 2.5t |
% growth | (2 %) | 9 % | 22 % | 25 % | 13 % | 16 % | 17 % |
EBITDA | 134.3b | 137.5b | 203.1b | 302.9b | 307.4b | 378.0b | 503.1b |
% EBITDA margin | 14 % | 13 % | 16 % | 19 % | 17 % | 18 % | 20 % |
Profit | 76.0b | 67.0b | 109.2b | 200.7b | 208.7b | 263.6b | 364.7b |
% profit margin | 8 % | 6 % | 9 % | 13 % | 11 % | 13 % | 15 % |
EV / revenue | 5.8x | 4.3x | 7.0x | 5.4x | 5.9x | 5.1x | 4.3x |
EV / EBITDA | 41.3x | 32.4x | 44.3x | 28.4x | 35.1x | 28.4x | 21.3x |
R&D budget | 227.4b | 260.2b | 341.6b | 365.2b | - | - | - |
R&D % of revenue | 24 % | 25 % | 27 % | 23 % | - | - | - |
Source: Dealroom estimates
Date | Investors | Amount | Round |
---|---|---|---|
N/A | N/A | IPO | |
Total Funding | - |
Recent News about Daiichi Sankyo
EditTech stack
Tech stackLearn more about the technologies and tools that this company uses.
exited
ACQUISITION by Daiichi Sankyo Feb 2011
ACQUISITION by Daiichi Sankyo Sep 2014
exited
ACQUISITION by Daiichi Sankyo May 2008
ACQUISITION by Daiichi Sankyo Oct 2015
exited
ACQUISITION by Daiichi Sankyo Apr 2006
ACQUISITION by Qol Holdings Oct 2023